Biotecnol SA

biotecnol3.jpg

General Information

Company Name
Biotecnol SA
Year founded
1996
Headquarters
Lagoas Park - Oeiras, Portugal
Subsidiaries
Biotecnol Pharmaceuticals Inc - USA, Durham, North Carolina
Management Team
Pedro de Noronha Pissara, PhD - Chief Executive Officer
Andrew Kelly, PhD - Chief Scientific Officer
José Luis Moreira, PhD - Chief Financil Officer
Phillip Cunnah, PhD - Senior Director: Development & Manufacturing
Bernard Brigonnet - Chief Business Officer
Didier Landais - Chief Development Officer
Nico Mertens, PhD - Director of Antibody Engineering
Miroslav Ravic, PhD - Clinical Advisor
Shareholders
Company founders, private investors and employees
Corporate Investors: Pharmis, LDA and Iberfar SA
INOV Capital - Sociedade de Capital de Risco
Taguspark, SA
Grupo José de Mello, SGPS, SA
Luso American Foundation - FLAD
Income
No financial data available
website
http://www.biotecnol.com/

Biotecnol SA is a Portuguese biopharmaceutical company focused on the discovery, engineering and development of novel multifunctional antibody molecules directed to key therapeutic targets.
The
lagoaspark2.jpg
Lagoas Park
company has its headquarters in Lagoas Park, Oeiras, where it has its own 800m² modern facilities designed specifically for the development of biological products. Biotecnol's activities can be divided in five major departments:

  • Molecular Biology;
  • Fermentation;
  • Downstream Processing;
  • Bioassays;
  • Analytics;

Apart from its headquarters in Portugal, Biotecnol also has a subsidiary, Biotecnol Pharmaceuticals Inc, in Durham, North Carolina USA,that operates adjacent to the Research Triangle Park. Here, the regulatory pre-clinical and clinical development of the antibody products pipeline is carried out. Meanwhile, all process development and manufacturing activities are done in Portugal.

All of the above general information can be seen in depth at //http://www.biotecnol.com///
Lagoas Park image taken from www.logismarket.pt.

History


Biotecnol's time line[1] :
  • Late 1996 - This is the year the company was founded. Biotecnol started as a consultancy company;
  • 1997-1999 - In the beginning the company had its laboratories at the Center for Biological and Chemical Engineering (CEQB) at the Instituto Superior Técnico (IST). Its head offices were at Taguspark;
  • 2000 - Some investment enabled the company to begin activities independently from CEQB. This investment allowed Biotecnol to invest in its own technology, network, clients, people and also to put its structure into place. Thereby, Biotecnol developed into the first company in Portugal whose focus was the research & development of pharmaceutical biotechnology;
  • 2002 - The company makes the transition from a technology development company to a product development company, due to additional financing;
  • 2004 - Biotecnol started the development of a pipeline of products in the oncology field and obtained granted patents on antibody engineering technology;
  • 2006 - Biotecnol moved to its new facilities and offices at Lagoas Park;
  • 2008 - The company started its activity abroad, more specifically in the United States of America. Biotecnol opened a subsidiary called Biotecnol Pharmaceutical Inc, in Durham, NC;
  • Onwards - The company plans to expand its product development activities from the USA base;


Technology/R&D


Biotecnol believes that technology adds value to the company as it supports the development of the company's own product candidates. Biotecnol has various types of antibody formats in development against various cancer targets in a diverse pipeline of antibody products.
  • Technology
Biotecnol developed the Tribody technology[2] in order to provide a multifunctional recombinant antibody platform which had a longer serum half life than bi-specific antibodies, but which had similar tissue penetration. The following image was taken from the brochure that corresponds to the second reference.

tribody.jpg
Tribody technology
  • Research & Development[3]
Biotecnol set up R&D collaborations in order to develop both products and technology so they could extend their expertise. Biotecnol makes R&D with external sources to understand and validate biological mechanisms of action, product discovery, data gathering for IND submission and supporting pre-clinical activities. Nowadays, Biotecnol collaborates with VIB, Flanders Interuniversity Institute for Biotechnology, Belgium, and with CIPERB, University of Naples, Italy. With the VIB collaboration both have developed FastScreen® which is a technological concept that allows the analysis of expression of a given gene in the shortest possible time span. With CIPERB, the collaboration aims on the development of anti-HER2 immunoagents as well as on the study of their respective mechanisms of action and the biology of the EGFR receptor.

Tribody Technology image taken from www.biotecnol.com.


Products


Biotecnol applies its antibody technologies, product development and manufacturing experience to generate, support and potentially license out human antibody products.The company is focused on Oncology and their main products[4] are:
  • anti-HER2/CAB051
CAB051 is an antibody that could be an alternative to the existing anti-HER2 antibodies. They may be useful in combination with upstream-downstream HER2 pathways effectors and may be administered in patients that present cardiotoxicity symptoms during treatment with other HER2 antibodies and/or anthracyclines;

  • anti-HSP90
HSP90 is a molecular chaperone that facilitates protein folding in both tumor and normal cells. It has been shown to be over expressed in a wide variety of cancer and virally-transformed cells. It is essential to cell survival and plays a role in regulating mitogenesis and cell-cycle progression. Targeting the overexpression of intracellular Hsp90 in cancer is already possible with some compounds who are not effective for the extracellular Hsp90. Yet, it has been shown that the inhibition of extracellular Hsp90 by antibodies reduces the migration rate of cancer cells in vitro;
  • Cardiotrophin I
It is known, through intensive studies, that liver failure can lead to the development of cancer.Treatment with recombinant CT-1 is able to prevent Fas-induced apoptosis in various models of acute liver failure and it can also reduce liver damage when given up to 3 hours after Fas-ligation. This suggests that CT-1 can block apoptotic process when administered early after injury which increases its therapeutic potential;
  • anti-PTHrP
PTHrP has been identified as an essential survival factor for human renal cell carcinoma. The blockade of PTHrp with antibodies induces tumor regression by inducing cell apoptosis;

Simão Castro, nº57841, MEBiol

  1. bioinformatics
  2. biopharmaceutical
  3. company
  4. genetic tests
  5. monoclonal antibodies
  6. nanobiotechnology
  7. penicillin; antibiotics
  8. pharmaceutical
  9. poland
  10. portugal
  11. product
  12. technology
  13. tool
  14. vaccine

  1. ^ http://www.biotecnol.com/biotecnol/common1.aspx?node=00004101:00000001:00000001:00000002
  2. ^ http://www.biotecnol.com/zoom8/upload/editor/225/File/Tribody%20Brochure%202006.pdf
  3. ^ http://www.biotecnol.com/biotecnol/common1.aspx?node=00004101:00000001:00000003

  4. ^ http://www.biotecnol.com/biotecnol/common1.aspx?node=00004101:00000001:00000002